Zeynep Irem Ozay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeynep Irem Ozay has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Neeraj Agarwal
Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, USA
18 shared publications - Chadi Hage Chehade
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
17 shared publications - Umang Swami
Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
16 shared publications - Nicolas Sayegh
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
15 shared publications - Gerald Li
Foundation Medicine, Cambridge, Massachusetts
13 shared publications - Rana R. McKay
Division of Medical Oncology University of California, San Diego Moores Cancer Center San Diego California USA
13 shared publications
Latest Publications
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 3
Survival Outcomes Based on Line of Therapy and Treatment Trends With Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
PURPOSE: The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the recent approvals of lutetium Lu 177 vipivotide tetraxetan and poly (ADP-ribose) polymerase inhibitors, adding new layers of complexity to treatment sequencing. Cabazitaxel is an approved option in patients with disease progression on docetaxel. Real-world data on the effectiveness of cabazitaxel by line of therapy remain limited. To address this gap, we evaluated survival outcomes based on line of therapy in patients with mCRPC receiving single-agent cabazitaxel in a large real-world database. METHODS: This retrospective study used the US-based Flatiron Health electronic health record–derived deidentified database. Patients who were diagnosed with mCRPC and received single-agent cabazitaxel for the first time were eligible and included. Real-world time to next treatment (rwTTNT) and real-world overall survival (rwOS) were calculated from the date patients initiated the first cycle of cabazitaxel. Survival rates were summarized using medians and 95% CI using the Kaplan-Meier method. RESULTS: Among 24,105 patients with metastatic prostate cancer in the data set, 1,315 patients with mCRPC were eligible and included. The median age was 73 years (IQR, 67-78). The majority were non-Hispanic White (62%), treated in community practice (84%), had commercial insurance (81%), and received treatment in fourth line or later (58%). For the overall cohort, the median rwTTNT was 4.7 months (95% CI, 4.4 to 5.0), and the median rwOS was 8.6 months (95% CI, 8.0 to 9.3). The median rwTTNT ranged from 4.2 months to 6.8 months, and rwOS ranged from 6.3 months to 14 months based on the line of therapy. CONCLUSION: In this large, real-world study of patients with mCRPC, cabazitaxel retained its effectiveness regardless of its line of therapy.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 3
Survival Outcomes Based on Line of Therapy and Treatment Trends With Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
PURPOSE: The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the recent approvals of lutetium Lu 177 vipivotide tetraxetan and poly (ADP-ribose) polymerase inhibitors, adding new layers of complexity to treatment sequencing. Cabazitaxel is an approved option in patients with disease progression on docetaxel. Real-world data on the effectiveness of cabazitaxel by line of therapy remain limited. To address this gap, we evaluated survival outcomes based on line of therapy in patients with mCRPC receiving single-agent cabazitaxel in a large real-world database. METHODS: This retrospective study used the US-based Flatiron Health electronic health record–derived deidentified database. Patients who were diagnosed with mCRPC and received single-agent cabazitaxel for the first time were eligible and included. Real-world time to next treatment (rwTTNT) and real-world overall survival (rwOS) were calculated from the date patients initiated the first cycle of cabazitaxel. Survival rates were summarized using medians and 95% CI using the Kaplan-Meier method. RESULTS: Among 24,105 patients with metastatic prostate cancer in the data set, 1,315 patients with mCRPC were eligible and included. The median age was 73 years (IQR, 67-78). The majority were non-Hispanic White (62%), treated in community practice (84%), had commercial insurance (81%), and received treatment in fourth line or later (58%). For the overall cohort, the median rwTTNT was 4.7 months (95% CI, 4.4 to 5.0), and the median rwOS was 8.6 months (95% CI, 8.0 to 9.3). The median rwTTNT ranged from 4.2 months to 6.8 months, and rwOS ranged from 6.3 months to 14 months based on the line of therapy. CONCLUSION: In this large, real-world study of patients with mCRPC, cabazitaxel retained its effectiveness regardless of its line of therapy.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (4) , 708-716
International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings
PURPOSE: Despite international medical graduates (IMGs) accounting for up to one third of all practicing oncologists in the United States, and nearly half of fellowship trainees, little is known about their contributions to presentations at international oncology meetings. Therefore, we investigated the representation of IMGs in invited faculty roles at the ASCO Annual Meeting as a representative example. METHODS: Presentation data from ASCO 2022 and 2023 Annual Meetings were obtained from program guides. We collected presentation-level and speaker-level variables of invited faculty roles and original research. Speakers were categorized as American medical graduate (AMG), IMG, non–US-based, or non-MD (Doctor of Medicine). Univariable and multivariable analyses assessed factors influencing selection for invited faculty roles. RESULTS: A total of 2,590 presentations by 2,109 unique speakers were reviewed, including primary research presenters and invited faculty. Among the 1,352 presentations by AMGs, 30% were primary research and 70% were invited faculty roles. For the 374 presentations by IMGs, 41% were primary research and 59% were invited faculty roles. Notably, first-author IMGs were significantly less likely to receive invited faculty roles relative to their primary research output compared with first-author AMGs (adjusted odds ratio, 0.69 [95% CI, 0.53 to 0.90]; P = .006), even when accounting for academic rank, presumed sex, and year. CONCLUSION: Relative to IMGs' original research output, IMGs appear to receive fewer invitations for ASCO Annual Meeting invited faculty roles compared with AMGs. Our findings suggest potential underrepresentation and under-recognition of IMGs in these roles, despite their contributions to the oncology workforce in the United States.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (4) , 708-716
International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings
PURPOSE: Despite international medical graduates (IMGs) accounting for up to one third of all practicing oncologists in the United States, and nearly half of fellowship trainees, little is known about their contributions to presentations at international oncology meetings. Therefore, we investigated the representation of IMGs in invited faculty roles at the ASCO Annual Meeting as a representative example. METHODS: Presentation data from ASCO 2022 and 2023 Annual Meetings were obtained from program guides. We collected presentation-level and speaker-level variables of invited faculty roles and original research. Speakers were categorized as American medical graduate (AMG), IMG, non–US-based, or non-MD (Doctor of Medicine). Univariable and multivariable analyses assessed factors influencing selection for invited faculty roles. RESULTS: A total of 2,590 presentations by 2,109 unique speakers were reviewed, including primary research presenters and invited faculty. Among the 1,352 presentations by AMGs, 30% were primary research and 70% were invited faculty roles. For the 374 presentations by IMGs, 41% were primary research and 59% were invited faculty roles. Notably, first-author IMGs were significantly less likely to receive invited faculty roles relative to their primary research output compared with first-author AMGs (adjusted odds ratio, 0.69 [95% CI, 0.53 to 0.90]; P = .006), even when accounting for academic rank, presumed sex, and year. CONCLUSION: Relative to IMGs' original research output, IMGs appear to receive fewer invitations for ASCO Annual Meeting invited faculty roles compared with AMGs. Our findings suggest potential underrepresentation and under-recognition of IMGs in these roles, despite their contributions to the oncology workforce in the United States.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Sensitivity analysis: non-MSI-H comparison. (A) Standardized mean difference is shown for features pre- and post- adjustment for the TMB10+ cohort. Propensity-adjusted comparison of ICI (tTMB≥10) vs. taxanes (any tTMB level) is shown for (B) TTNT and (C) OS among the cohort excluding MSI-H.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Sensitivity analysis: non-MSI-H comparison. (A) Standardized mean difference is shown for features pre- and post- adjustment for the TMB10+ cohort. Propensity-adjusted comparison of ICI (tTMB≥10) vs. taxanes (any tTMB level) is shown for (B) TTNT and (C) OS among the cohort excluding MSI-H.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Genetic Ancestry and tTMB and tMSI associations. Associations between tMSI and tTMB categories are shown in relation to genetic ancestry.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Genetic Ancestry and tTMB and tMSI associations. Associations between tMSI and tTMB categories are shown in relation to genetic ancestry.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Pre-adjustment and post-adjustment cohort Imbalances. Standardized mean difference is shown for features pre- and post- adjustment for the (A) TMB10+ cohort and (B) TMB < 10 cohort.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Pre-adjustment and post-adjustment cohort Imbalances. Standardized mean difference is shown for features pre- and post- adjustment for the (A) TMB10+ cohort and (B) TMB < 10 cohort.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Clinical and Pathological Features of Treatment Assignment by Treatment Assignment
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Clinical and Pathological Features of Treatment Assignment by Treatment Assignment
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Purpose:Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC.Experimental Design:This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane.Results:Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%.Conclusions:These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Purpose:Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC.Experimental Design:This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane.Results:Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%.Conclusions:These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Multivariable Outcomes by Biomarker Status on Chemo. Adjusting for potential known confounders, multivariable models evaluating (A) TTNT and (B) OS are shown.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Multivariable Outcomes by Biomarker Status on Chemo. Adjusting for potential known confounders, multivariable models evaluating (A) TTNT and (B) OS are shown.
- Open Access
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Multivariable Outcomes by Biomarker Status on ICI. Adjusting for potential known confounders, multivariable models evaluating (A) TTNT and (B) OS are shown.
- 17 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Multivariable Outcomes by Biomarker Status on ICI. Adjusting for potential known confounders, multivariable models evaluating (A) TTNT and (B) OS are shown.
- Open Access
- 4 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 801-812
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%. Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.
- 4 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 801-812
Open AccessAdditive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB <10 without tMSI-H group. In intrapatient assessments, patients with tTMB ≥10 had more favorable TTNT with subsequent ICI versus prior taxane. Detection of bMSI-H was associated with more favorable TTNT on ICI (HR, 0.34; 95% CI, 0.14–0.83) and OS (HR, 0.21; 95% CI, 0.06–0.75) when tumor fraction ≥1%. Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.